Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JCAR 014

Drug Profile

JCAR 014

Alternative Names: 4-1BB-modified CAR CD8+ central memory and CD4+ T lymphocyte therapy - Juno Therapeutics; anti-CD19-4-1BB-zeta modified CAR CD8+ central memory and CD4+ T lymphocyte therapy - Juno Therapeutics; anti-CD19/4-1BB/zeta modified CAR CD8+ central memory and CD4+ T lymphocyte therapy - Juno Therapeutics; JCAR014

Latest Information Update: 13 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer AstraZeneca; Fred Hutchinson Cancer Research Center; Juno Therapeutics; National Cancer Institute (USA)
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 07 Apr 2022 Fred Hutchinson Cancer Research Center terminates a phase Ib trial in Non-Hodgkin’s lymphoma (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (IV) due to slow accrual (NCT02706405)
  • 11 Dec 2021 Efficacy and adverse events data from a phase I/II trial in Acute lymphoblastic leukaemia, Non-Hodgkin's lymphoma and Chronic lymphocytic leukaemia presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2021)
  • 09 Jun 2021 Updated efficacy and safety data from a phase I/II trial in Non-Hodgkin's lymphoma presented at the 26th Congress of the European Haematology Association (EHA-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top